Compare · Healthcare
Dr. Reddy's vs Sun Pharma: how their businesses differ
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY26, Sun Pharma's revenue of ₹58,462 cr was about 1.7 times Dr. Reddy's ₹33,700 cr (Cityfort calculation: one divided by the other).
Dr. Reddy's largest segment is Global Generics, 88.9% of revenue in FY26; Sun Pharma's largest segment is India, 33.8% of revenue in FY26.
India brought in 19.2% of Dr. Reddy's revenue in FY26.
Dr. Reddy's largest payer group is Buyers of finished medicines, 88.9% of revenue (FY26); Sun Pharma's largest payer group is Buyers in India, 33.8% of revenue (FY26).
Dr. Reddy's page lists Sun Pharma among its competitors; Sun Pharma's page does not list Dr. Reddy's.
Sources: Dr. Reddy's S11, S1, S12, S2 · Sun Pharma S1, S27, S18
Each company in 5 points
Dr. Reddy's
1 · What it sells
The company makes generic and branded medicines and the active ingredients that go into them, and its FY26 revenue from operations was ₹33,700 crore.
Sources and detail on the Dr. Reddy's page2 · Who pays it
In FY26, customers in the US paid 35.1% of the company's revenue, customers in India 19.2%, Russia 10.4% and all other countries 35.3%.
Sources and detail on the Dr. Reddy's page3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, including ₹1,358 crore of other income, the company kept ₹12.0 as profit for shareholders, and its operating EBITDA margin on revenue was 19.1% (Cityfort calculation, after ₹352 crore of write-downs).
Sources and detail on the Dr. Reddy's page4 · Where the operating profit comes from
Global Generics earned ₹16,970 crore of the company's ₹17,728 crore FY26 gross profit, while active ingredients and services (PSAI) earned ₹600 crore.
Sources and detail on the Dr. Reddy's page5 · The one thing to watch
US lenalidomide exclusivity ended in Jan 2026, and the company's North America revenue was ₹2,489 crore in Q2 FY27, 23% lower than a year earlier by its own count.
Sources and detail on the Dr. Reddy's page
Sun Pharma
1 · What it sells
Sun Pharma makes branded medicines for India, generic medicines for the US and other countries, and patented drugs such as Ilumya, and its FY26 revenue from operations was ₹58,462 crore.
Sources and detail on the Sun Pharma page2 · Who pays it
In FY26, buyers in India paid 33.8% of Sun Pharma's sales, buyers in the US 30.3%, emerging markets 20.1% and the rest of the world 15.8%.
Sources and detail on the Sun Pharma page3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, Sun Pharma kept ₹19.0 as profit after ₹2.2 of one-off charges, and in Q2 FY27 a ₹1,269 crore one-off charge cut profit to ₹1,989 crore while profit before one-off items and tax rose 6.3% to ₹4,428 crore.
Sources and detail on the Sun Pharma page4 · Where the operating profit comes from
Sun Pharma does not report profit by region or product, so the source of its FY26 EBITDA of ₹16,424 crore is not disclosed; patented innovative medicines were 20.7% of its sales, excluding a milestone payment.
Sources and detail on the Sun Pharma page5 · The one thing to watch
Sun Pharma agreed on 27 Apr 2026 to buy Organon, a company with US$6.2 billion of 2025 revenue, for an enterprise value of US$11.75 billion, and management said on 30 Oct 2026 it expects completion in Q4 FY27.
Sources and detail on the Sun Pharma page
Where each ₹100 went
Each company's own receipt for its latest full financial year, with matching lines in the same order where both have them.
Dr. Reddy's
Where ₹100 went · FY26
| Materials and goods bought | ₹34.9 |
|---|---|
| Employees | ₹17.1 |
| Other running costs (incl. write-downs) | ₹25.7 |
| Depreciation and amortisation | ₹5.9 |
| Interest | ₹1.1 |
| Income tax | ₹3.5 |
| Kept as profit for shareholders | ₹12.0 |
| Total | ₹100 |
Cityfort calculation from the FY26 audited results: each line ÷ ₹35,110 crore that came in (revenue ₹33,700 crore, other income ₹1,358 crore, and ₹52 crore from associates and minority partners' share of losses). Other running costs include ₹352 crore of write-downs. ₹12.0 was kept as profit; rounded lines add to 100.2.
Sun Pharma
Where ₹100 went · FY26
| Materials and goods bought | ₹19.1 |
|---|---|
| Employee costs | ₹18.9 |
| Other running costs (research, marketing, freight) | ₹29.4 |
| Depreciation, interest and small items | ₹5.5 |
| One-off charges | ₹2.2 |
| Income tax | ₹5.9 |
| Kept as profit for shareholders | ₹19.0 |
| Total | ₹100 |
Of every ₹100 that came in during FY26 (revenue of ₹58,462 crore plus ₹1,972 crore of other income), Sun Pharma kept ₹19.0 as profit for shareholders, after ₹2.2 of one-off charges.
Line items differ because each company groups its costs its own way in its filings. Only on Dr. Reddy's receipt: Employees; Other running costs (incl. write-downs); Depreciation and amortisation; Interest. Only on Sun Pharma's receipt: Employee costs; Other running costs (research, marketing, freight); Depreciation, interest and small items; One-off charges.
Revenue, net profit and free cash flow
Up to five financial years for each company, drawn on one shared scale per measure. Amounts in ₹ crore as each company reports them.
Revenue
Dr. Reddy's
Sun Pharma
See the numbers
Net profit
Dr. Reddy's
Sun Pharma
See the numbers
Free cash flow
Dr. Reddy's
Sun Pharma
See the numbers
Sources: Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12 · Sun Pharma S7, S6, S5, S1
Growth and net margin, FY22 to FY26
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net profit as a share of revenue, as on each page.
Dr. Reddy's
- Revenue, per year
- +11.8%
- Net profit, per year
- +17.7%
Sun Pharma
- Revenue, per year
- +10.9%
- Net profit, per year
- +36.8%
Cityfort calculation: compound growth per year from FY22 to FY26 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Sources: Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12 · Sun Pharma S7, S6, S5, S1
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
Dr. Reddy's
Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26
| Measure | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | ₹8,698 cr | ₹8,828 cr | −1.5% |
| Net profit | ₹925 cr | ₹1,347 cr | −31.3% |
Sun Pharma
Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26
| Measure | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | ₹16,199 cr | ₹14,478 cr | +11.9% |
| Net profit | ₹1,989 cr | ₹3,118 cr | −36.2% |
Sources: Dr. Reddy's S17, S14, S11, S12, S7, S8, S3, S4 · Sun Pharma S9, S20, S17, S13
Who pays each company
Dr. Reddy's
- Buyers of finished medicines · 88.9% of revenueWholesalers, distributors, pharmacy chains, hospitals and government institutions buying the Global Generics segment's medicines. Share is of FY26 revenue.
- Other drug makers · 10.5% of revenueBuy active ingredients and contract research and manufacturing services (PSAI segment). Share is after removing PSAI's sales to Dr. Reddy's own generics business.
- Others · 0.6% of revenueAurigene Oncology (a drug discovery business) and proprietary products.
Sun Pharma
- Buyers in India · 33.8% of revenueMedicines sold in India, mostly under Sun Pharma's brands. Its sales team of over 16,000 people visits doctors. Share is of FY26 sales; drug-ingredient sales are counted in the region where they were sold.
- Buyers in the US · 30.3% of revenueGeneric and innovative medicines sold in the US. US formulation sales were US$1,904 million in FY26.
- Buyers in emerging markets · 20.1% of revenueMedicines sold in emerging markets. Formulation sales there were US$1,265 million in FY26, up 13%.
- Buyers in the rest of the world · 15.8% of revenueMedicines sold in other countries. Formulation sales there were US$969 million in FY26, up 14%.
Revenue by segment
Dr. Reddy's
FY26
| Segment | Revenue | Share |
|---|---|---|
| Global Generics | ₹29,946 cr | 88.9% |
| Pharmaceutical Services and Active Ingredients (PSAI) | ₹3,540 cr | 10.5% |
| Others | ₹214 cr | 0.6% |
Sun Pharma
FY26
| Segment | Revenue | Share |
|---|---|---|
| India | ₹19,694 cr | 33.8% |
| United States | ₹17,620 cr | 30.3% |
| Emerging markets | ₹11,684 cr | 20.1% |
| Rest of the world | ₹9,222 cr | 15.8% |
Where the revenue comes from
Revenue by region, as each company splits it, with the period.
Dr. Reddy's
FY26
- United States35.1%
- India19.2%
- Russia10.4%
- Other countries35.3%
Sun Pharma
Not on the Sun Pharma page.
Sources: Dr. Reddy's S1
Borrowings and cash
Dr. Reddy's
- Borrowings
- ₹5,826 cr
- Cash and investments
- ₹6,874 cr
On 30 Sep 2026.
On 30 Sep 2026 Dr. Reddy's cash and short-term investments were ₹1,048 crore more than its borrowings (Cityfort calculation from the Q2 FY27 results).
Sun Pharma
- Borrowings
- ₹2,694 cr
- Cash and investments
- ₹33,570 cr
On 30 Sep 2026.
On 30 Sep 2026 Sun Pharma's cash and liquid investments were ₹30,877 crore more than its borrowings, before it raised ₹7,816 crore through bonds in Oct 2026.
Sources: Dr. Reddy's S3, S5, S6, S19, S22, S38 · Sun Pharma S9, S1, S56, S40, S11, S44
Who owns each company
Dr. Reddy's
- Promoters: 26.6%
- Foreign institutional investors (FIIs): 20.3%
- Indian institutions (DIIs): 31.9%
- Public: 9.9%
- Shares behind US-listed ADRs (held by JP Morgan Chase Bank as depository; filed inside foreign institutions): 11.1%
- Pledged: 0.0% of the promoter holding.
- Shareholding pattern at the end of Q2 FY27.
Sun Pharma
- Promoters: 52.7%
- Foreign institutional investors (FIIs): 14.4%
- Indian institutions (DIIs): 22.3%
- Public: 10.7%
- Pledged: 0.0% of the promoter holding.
- Shareholding pattern at the end of Q2 FY27.
Sources: Dr. Reddy's S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S42 · Sun Pharma S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S38, S39, S46, S47
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
Dr. Reddy's
- Own ingredient supply
The PSAI segment makes active ingredients and sold ₹727 crore of them to Dr. Reddy's own generics business in FY26. ICRA (Jan 2026) says this backward integration gives a significant cost advantage.
- Spread across markets
In FY26 customers in the US paid 35.1% of revenue, India 19.2%, Russia 10.4% and other countries 35.3%. It sold in 87 countries.
- US filings pipeline
77 generic and 3 new-drug applications were pending with the US FDA in Sep 2026, including 27 first-to-file.
- India brands
The company says, citing IQVIA, it ranked 8th in India in the quarter to Sep 2026, and its India sales grew 21.0% against the market's 14.7%.
- Cash and borrowings
On 30 Sep 2026 cash and short-term investments exceeded borrowings by ₹1,048 crore (Cityfort calculation). ICRA rated it AA+/Stable on 9 Jan 2026.
Sun Pharma
- Size in India
₹21,538 crore of India medicine sales and an 8.5% share in the 12 months to Jun 2026 (AIOCD), against 5.9% for the next name in the same list (Abbott, Abbott Healthcare and Novo combined).
- Reach to doctors
Over 16,000 field staff on 30 Jun 2026. Sun Pharma says it ranks first by prescriptions among 12 groups of doctors (SMSRC data).
- Brands
30 of India's top 300 medicine brands (AIOCD, Jun 2026). Its top 10 brands were about 17% of India revenue, so sales are spread across many brands.
- Product approvals
561 approved US generic applications and 58 approved new-drug applications on 30 Sep 2026, with 120 and 12 more pending.
- Cash on hand
On 30 Sep 2026 cash and liquid investments of ₹33,570 crore exceeded borrowings of ₹2,694 crore. CRISIL rated Sun Pharma AAA/Stable on 13 Oct 2026.
Sources: Dr. Reddy's S1, S38, S2, S5, S3, S72 · Sun Pharma S27, S10, S9, S40
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
Dr. Reddy's
- Semaglutide (diabetes and weight-loss injection) · Behind: behind the company's own plan₹239.7 crore provision, Q1 FY27
- India · Working: on track against what the company said+17% YoY, Q2 FY27 (company figure)
- Emerging markets · Working: on track against what the company said+24% YoY, Q2 FY27 (company figure)
- North America without lenalidomide · Mixed: partly on track₹2,489 crore, −23% YoY, Q2 FY27
- Europe and nicotine gums · Mixed: partly on track+1% YoY, Q2 FY27 (company figure)
- Abatacept biosimilar · Early: too early to judgeUS approval awaited
Sun Pharma
- Branded medicines in India · Working: on track against what the company saidIndia sales +17.3%, Q2 FY27
- Innovative medicines · Working: on track against what the company saidUS$1,420 million, FY26 (+16.4% excluding a milestone payment)
- US generics · Mixed: partly on trackUS$455 million, Q2 FY27 (−8.2%)
- Organon purchase · Early: too early to judgeEnterprise value US$11.75 billion; not closed
- New plant in Madhya Pradesh · New: recently announced₹3,000 crore, approved 2 Dec 2025
Sources: Dr. Reddy's S64, S67, S41, S8, S70, S5, S12, S38, S6, S48 · Sun Pharma S10, S18, S12, S11, S45, S50
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the statutory auditor and the latest credit rating, as each page records them.
Dr. Reddy's
- Dividends per shareFY22: ₹6.00 (22.8% of profit) · FY23: ₹8.00 (14.7% of profit) · FY24: ₹8.00 (11.9% of profit) · FY25: ₹8.00 (11.8% of profit) · FY26: ₹8.00 (15.9% of profit)
- BuybacksNone on the page in the last five years.
- AuditorDeloitte Haskins & Sells LLP, since 2026
- Credit ratingICRA: [ICRA]AA+ (long-term bank limits, ₹2,000 crore), outlook Stable (9 Jan 2026)
Sun Pharma
- Dividends per shareFY22: ₹10.00 (73.5% of profit) · FY23: ₹11.50 (32.6% of profit) · FY24: ₹13.50 (33.8% of profit) · FY25: ₹16.00 (35.1% of profit) · FY26: ₹16.00 (33.5% of profit)
- BuybacksNone on the page in the last five years.
- AuditorS R B C & Co LLP
- Credit ratingCRISIL: AAA (long term), A1+ (short term), outlook Stable (13 Oct 2026)
Sources: Dr. Reddy's S1, S25, S24, S22, S19, S12, S11, S46, S38 · Sun Pharma S3, S7, S6, S5, S1, S40
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: competition, regulation, legal cases. Every risk is on each company's page.
Dr. Reddy's
- Semaglutide supply problem (execution)On 9 Jul 2026 the company said semaglutide batches failed specification because of an ingredient (API) issue. Q1 FY27 carried a ₹239.7 crore provision for inventory and related costs.
- Weaker cash flow in H1 FY27 (liquidity)Operating cash flow was ₹435 crore in H1 FY27, against ₹3,020 crore in H1 FY26. After ₹802 crore of capex, free cash flow was −₹367 crore.
- Write-downs on research bets (execution)FY26 included ₹352 crore of write-downs, among them ₹129.1 crore for a stopped CAR-T programme and ₹91.4 crore for eftilagimod alfa, whose Phase III trial was stopped for futility.
Sun Pharma
- Organon purchase and new debt (debt)The Organon purchase has not closed. CRISIL says it will be funded with US$2.0–2.5 billion of cash and US$9.5–10.0 billion of debt. Sun Pharma's borrowings were ₹2,694 crore on 30 Sep 2026. Organon deal costs were ₹513 crore in H1 FY27, and Sun Pharma expects more.
- Small promoter pledge (governance)On 30 Sep 2026, 85,000 promoter-group shares held by Kumud Shantilal Shanghvi were pledged, 0.01% of the promoter holding. Pledged shares are given as loan collateral; a lender can sell them if a loan is not repaid.
Sources: Dr. Reddy's S41, S8, S6, S3, S17, S12, S62, S11 · Sun Pharma S40, S9, S12, S39, S38
Key facts
- How does Dr. Reddy's make money compared with Sun Pharma?
- Dr. Reddy's revenue by segment in FY26: Global Generics 88.9%, Pharmaceutical Services and Active Ingredients (PSAI) 10.5%, Others 0.6%. Sun Pharma's revenue by segment in FY26: India 33.8%, United States 30.3%, Emerging markets 20.1%, Rest of the world 15.8%.
- Which is bigger by revenue, Dr. Reddy's or Sun Pharma?
- Dr. Reddy's reported revenue of ₹33,700 cr in FY26, and Sun Pharma reported revenue of ₹58,462 cr in FY26.
- How much net profit did Dr. Reddy's and Sun Pharma report?
- Dr. Reddy's reported a net profit of ₹4,196 cr in FY26, and Sun Pharma reported ₹11,479 cr in FY26.
- How much of every ₹100 did Dr. Reddy's and Sun Pharma keep as profit?
- Dr. Reddy's kept ₹12.0 of every ₹100 that came in during FY26, and Sun Pharma kept ₹19.0 in FY26 (Cityfort calculation from each company's annual report).
- How much do Dr. Reddy's and Sun Pharma owe, and how much cash do they hold?
- Dr. Reddy's had borrowings of ₹5,826 cr and cash and investments of ₹6,874 cr on 30 Sep 2026. Sun Pharma had borrowings of ₹2,694 cr and cash and investments of ₹33,570 cr on 30 Sep 2026.
- Who owns Dr. Reddy's and Sun Pharma?
- Promoters held 26.6% of Dr. Reddy's shares at the end of Q2 FY27, with none of it pledged. Promoters held 52.7% of Sun Pharma's shares at the end of Q2 FY27, and 0.0% of the promoter holding was pledged. Both come from the shareholding patterns the companies filed with NSE and BSE.
- When do Dr. Reddy's and Sun Pharma's financial years end?
- Dr. Reddy's and Sun Pharma both use the Indian financial year, April to March. The latest full year is FY26 on the Dr. Reddy's page and FY26 on the Sun Pharma page.
Sources: Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12, S2, S3, S5, S6, S38 · Sun Pharma S7, S6, S5, S1, S27, S18, S9, S56, S40, S11, S44
Built from each company's page. Dr. Reddy's updated 17 Nov 2026; Sun Pharma updated 11 Nov 2026.
Sources
Dr. Reddy's
- S1Integrated Annual Report FY2025-26, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 30 Jun 2026
- S2Business Responsibility and Sustainability Report FY2025-26, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 30 Jun 2026
- S3Q2 FY27 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 23 Oct 2026
- S4Q2 FY27 results filing: board outcome and financial results (PDF), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Oct 2026
- S5Q2 FY27 results presentation (IFRS), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Oct 2026
- S6Q2 FY27 earnings call transcript (23 Oct 2026), Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 29 Oct 2026), 29 Oct 2026
- S7Q1 FY27 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 22 Jul 2026
- S8Q1 FY27 results filing (PDF, notes), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 22 Jul 2026
- S11Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 12 May 2026
- S12Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 12 May 2026
- S14Q3 FY26 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 21 Jan 2026
- S17Q2 FY26 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 24 Oct 2025
- S19Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 9 May 2025
- S20Q4 FY25 results filing (PDF; FY24 comparatives and split-adjusted EPS), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 9 May 2025
- S22Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 7 May 2024
- S23Q4 FY24 results filing (PDF; FY23 comparatives), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 7 May 2024
- S24Q4 FY23 and FY23 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 10 May 2023
- S25Q4 FY22 and FY22 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 19 May 2022
- S26Shareholding pattern as of Dec 2023 (NSE XBRL), NSE (company filing), 19 Jan 2024
- S27Shareholding pattern as of Mar 2024 (NSE XBRL), NSE (company filing), 19 Apr 2024
- S28Shareholding pattern as of Jun 2024 (revised filing) (NSE XBRL), NSE (company filing), 19 Jul 2024
- S29Shareholding pattern as of Sep 2024 (NSE XBRL), NSE (company filing), 21 Oct 2024
- S30Shareholding pattern as of Dec 2024 (NSE XBRL), NSE (company filing), 21 Jan 2025
- S31Shareholding pattern as of Mar 2025 (NSE XBRL), NSE (company filing), 19 Apr 2025
- S32Shareholding pattern as of Jun 2025 (NSE XBRL), NSE (company filing), 21 Jul 2025
- S33Shareholding pattern as of Sep 2025 (NSE XBRL), NSE (company filing), 16 Oct 2025
- S34Shareholding pattern as of Dec 2025 (NSE XBRL), NSE (company filing), 20 Jan 2026
- S35Shareholding pattern as of Mar 2026 (revised filing) (NSE XBRL), NSE (company filing), 21 Jul 2026
- S36Shareholding pattern as of Jun 2026 (NSE XBRL), NSE (company filing), 21 Jul 2026
- S37Shareholding pattern as of Sep 2026 (NSE XBRL), NSE (company filing), 21 Oct 2026
- S38ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable), ICRA Ltd, 9 Jan 2026
- S41Intimation: semaglutide batches out of specification due to API issue; supplies delayed, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 9 Jul 2026
- S42Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 18 Sep 2025
- S46AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Jul 2026
- S48Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 25 Jun 2026
- S62Disclosure: Immutep update on TACTI-004 Phase III (eftilagimod alfa), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 13 Mar 2026
- S64Press release: launch of semaglutide injection (Obeda) in India, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 21 Mar 2026
- S67Press release: launch of generic semaglutide injection in Canada, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 16 May 2026
- S70Press release: marketing authorization for generic semaglutide injection in Brazil, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 5 Nov 2026
- S72Sun Pharmaceutical Industries: investor presentation, September 2026 ("Creating Lasting Value"), India market share chart (AIOCD AWACS, MAT Jun 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 Sep 2026
Sun Pharma
- S1Annual Report FY26: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 6 Jul 2026
- S3Annual Report FY26: Board's Report and Corporate Governance section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 6 Jul 2026
- S5Annual Report FY25: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 4 Jul 2025
- S6Annual Report FY24: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 8 Jul 2024
- S7Annual Report FY23: Consolidated Financial Statements section, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 27 Jul 2023
- S9Unaudited consolidated financial results Q2 FY27 (quarter and half year ended 30 Sep 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
- S10Press release: Sun Pharma reports Q2FY27 results, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
- S11Q2 FY27 earnings presentation, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 30 Oct 2026
- S12Q2 FY27 earnings call transcript (call 30 Oct 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 4 Nov 2026
- S13Unaudited consolidated financial results Q1 FY27 (quarter ended 30 Jun 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 31 Jul 2026
- S17Audited consolidated financial results Q4 FY26 and FY26, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 May 2026
- S18Press release: Sun Pharma reports Q4FY26 and FY26 results, Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 May 2026
- S20Unaudited consolidated financial results Q3 FY26 (quarter ended 31 Dec 2025), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 31 Jan 2026
- S27Investor presentation, September 2026 ("Creating Lasting Value"), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 Sep 2026
- S28Shareholding pattern as of 31 Dec 2023 (NSE XBRL), NSE (company filing), 16 Jan 2024
- S29Shareholding pattern as of 31 Mar 2024 (NSE XBRL), NSE (company filing), 18 Apr 2024
- S30Shareholding pattern as of 30 Jun 2024 (NSE XBRL), NSE (company filing), 19 Jul 2024
- S31Shareholding pattern as of 30 Sep 2024 (NSE XBRL), NSE (company filing), 16 Oct 2024
- S32Shareholding pattern as of 31 Dec 2024 (NSE XBRL), NSE (company filing), 20 Jan 2025
- S33Shareholding pattern as of 31 Mar 2025 (NSE XBRL), NSE (company filing), 17 Apr 2025
- S34Shareholding pattern as of 30 Jun 2025 (NSE XBRL), NSE (company filing), 21 Jul 2025
- S35Shareholding pattern as of 30 Sep 2025 (NSE XBRL), NSE (company filing), 16 Oct 2025
- S36Shareholding pattern as of 31 Dec 2025 (NSE XBRL), NSE (company filing), 15 Jan 2026
- S37Shareholding pattern as of 31 Mar 2026 (NSE XBRL, revised filing), NSE (company filing), 17 Jun 2026
- S38Shareholding pattern as of 30 Jun 2026 (NSE XBRL), NSE (company filing), 17 Jul 2026
- S39Shareholding pattern as of 30 Sep 2026 (NSE XBRL), NSE (company filing), 15 Oct 2026
- S40Credit rating intimation with CRISIL rationale (13 Oct 2026, NCDs assigned AAA/Stable) and ICRA rationale, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 13 Oct 2026
- S44Intimation: international credit ratings (Moody's Baa1, S&P BBB+), Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 8 Sep 2026
- S45Intimation and press release: definitive agreement to acquire Organon & Co., Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 27 Apr 2026
- S46Intimation: receipt of requests for reclassification from promoter group to public (Valia family), Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 14 May 2026
- S47Intimation: shareholders approve reclassification from promoter group to public, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 26 Sep 2026
- S50Intimation: approval of ₹3,000 crore greenfield formulations facility in Madhya Pradesh, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 2 Dec 2025
- S56Intimation: allotment of non-convertible debentures of ₹7,816 crore, Sun Pharmaceutical Industries Ltd (filing to NSE/BSE), 26 Oct 2026
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.